Does anyone know these two guys?>>>>>>>>>XOMA Announces New Executive Team Appointments; Expanded Business Development Function Sets Stage for Additional Collaborations
BERKELEY, Calif.--(BUSINESS WIRE)--Sept. 26, 2002--XOMA Ltd. (Nasdaq:XOMA), a biopharmaceutical company and early pioneer in antibody development, today announced key changes and additions to its senior management team. Michel Bergh, Ph.D., former vice president of business development at Nexell Therapeutics, has been named XOMA's new vice president of business development, responsible for heading up XOMA's licensing and collaboration initiatives. Additionally, Steve Carroll, XOMA's former vice president of pre-clinical development has taken on a new role of vice president, scientific and product development, where he will lead the technical assessment of business development opportunities. Robert Gundel, Ph.D., former vice president of pharmacology and pre-clinical research at Chiron, has been appointed to the position of vice president, preclinical research at XOMA.
"Bringing Michel Bergh on board and reassigning Steve Carroll highlight our commitment to strengthening our business development function. This group will work towards furthering our strategy of strengthening our product pipeline via collaborative arrangements with other companies, as well as leveraging XOMA's proprietary products and technologies," said Jack Castello, chairman, president and chief executive officer of XOMA. "In addition, Bob Gundel will bring over 20 years' experience and valuable new perspectives in his role as head of our preclinical group."
Prior to joining XOMA, Bergh was vice president of business development at Nexell Therapeutics, where he was involved in the re-alignment of Nexell's business strategy and merger and acquisition activities. Prior to joining Nexell, Dr. Bergh served as vice president, business development of LocalMed, Inc., a manufacturer of medical devices for interventional cardiology. Previously, Dr. Bergh held executive positions at Shaman Pharmaceuticals, Schering-Plough Corporation and Genzyme Corporation. Dr. Bergh received his postgraduate training at the Cancer Center of the Massachusetts Institute of Technology.
He received his M.S. in chemistry and pharmacology and Ph.D. in biochemistry from Vrije Universiteit in Amsterdam, the Netherlands.
Dr. Gundel was vice president of pharmacology and preclinical research at Chiron Corporation, where he coordinated drug discovery and development activities focused on small molecules, proteins, monoclonal antibodies and vaccines for disease indications, including cardiovascular disease, cancer and infectious diseases. Previously he worked at Bayer Corporation as the director of pharmacology, guiding internal research and external collaborations in several therapeutic areas including respiratory disease, cardiovascular and oncology. Earlier, Dr. Gundel was at Boehringer Ingelheim Pharmaceuticals, Inc., where much of his work focused on pulmonary inflammation. His education includes an M.S. and Ph.D. in physiology from New York Medical College and a B.A. in Biology from State University of New York.
About XOMA
XOMA develops and manufactures innovative biopharmaceuticals for disease targets that include cancer, immunological and inflammatory disorders, and infectious diseases. XOMA's programs include collaborations: with Genentech, Inc. on the Raptiva(TM) antibody for psoriasis (Phase III), rheumatoid arthritis (Phase II) and other indications; with Onyx Pharmaceuticals, Inc. to develop and manufacture its ONYX-015 product for various cancers (Phase II and III); with Baxter Healthcare Corporation to develop NEUPREX(R) (rBPI-21) for Crohn's disease (Phase II) and other indications; and with Millennium Pharmaceuticals, Inc. on two biotherapeutic agents, CAB2 and MLN01, for certain vascular inflammation indications (preclinical). Earlier-stage development programs include compounds to treat cancer, retinopathies, autoimmune diseases and infections. For more information about XOMA's pipeline and activities, please visit XOMA's website at www.xoma.com.
Statements made in this press release relating to future business and product development, or that otherwise relate to future periods, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 2E of the Securities Exchange Action of 12934. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. These risks, including those related to the availability of additional licensing or collaboration opportunities, results of pending and future pre-clinical research and other uncertainties, are discussed in XOMA's most recent annual report on Form 10K and in other SEC filings. Consider such risks carefully in evaluating XOMA's prospects.
CONTACT:
XOMA Ltd., Berkeley
Laura Zobkiw, 510/204-7200 (Investors and Media)
or
Kureczka/Martin Associates
Ellen M. Martin, 510/832-2044 (Investors and Media)
SOURCE: XOMA Ltd.
Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com
09/26/2002 07:29 EASTERN |
